Innovation

8 million of Americans are affected by hypertension which is a disease that affects heart functions and can ultimately cause death. Amongst these people, 58 million are treated with traditional medical treatment such as a diet with little salt and beta-blockers. For the majority of these patients, traditional treatments are not able to reduce hypertension because the correct hypertension should be diagnosed before choosing the right treatment. This is why the hypertension panel, made of Aldosterone and Renin, to diagnose the primary aldosteronism, is of key importance to detect the most spread out type of aldosteronism as the first step to prescribe the right treatment. We are the first and only company offering the hypertension panel on CLIA technology, increasing speed and precision in delivering results to our clients and, ultimately, to patients. We launched the chemiluminescent assay for Aldosterone at the end of 2012, the first example of such an assay on a high throughput random access platform. Innovation at DiaSorin regarding a monoclonal antibody and amplification of the chemiluminescent signal was crucial for allowing us to develop the Aldosterone assay. A few key immunoassays have remained in the Radioimmunoassay (RIA) format due to difficulties in making non-radioactive assays with sufficient sensitivity. Clearly, the radioactive assays have drawbacks, both for the end user and for the manufacturer, with environmental impact and short shelf life. The aldosteron